Insights - Amarin Corporation (AMRN) reported quarterly results on Friday morning, $0.02 ahead of consensus EPS but below expectations on the top-line with a $1.6M miss. Cost-cutting … Continue Reading
Read NowResearch - Albany Molecular (AMRI) management's ability to execute on an aggressive growth plan is central to the long thesis.
Read NowRecap - We count at least nine failures of one sort or another (Complete Response Letters, failed trials) in the last five days from companies such as Pozen (POZN), … Continue Reading
Read NowInsights - AVEO has lost more than 90% of its market valuation in the last 21 months; another of PropThink’s “Drugs that Disappointed in 2013.” In February, AVEO … Continue Reading
Read NowResearch - Synergy's phase 2 IBS-C results were, in our view, better than expected. But the market took a dim view of the stock on Wednesday for a number of reasons, outlined here.
Read NowResearch - Ironwood (IRWD) had a good quarter, and the next few quarters should look even better as an advertising campaign kicks off.
Read NowRecap - An update from Sarepta Therapeutics (SRPT) first thing on Monday morning caught the attention of the biotech world – and sent one of our 2014 recommendations to PropThink Premium … Continue Reading
Read Now
